Frontiers in Oncology (Aug 2023)

SARS-CoV-2 infection in high-risk children following tixagevimab–cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study

  • Diego R. Hijano,
  • Jose A. Ferrolino,
  • Elizabeth G. Swift,
  • Carolyn A. Michaels,
  • Anita Max,
  • Randall T. Hayden,
  • Joshua Wolf,
  • Joshua Wolf,
  • Ronald H. Dallas,
  • William L. Greene,
  • Julie L. Richardson,
  • Hana Hakim,
  • Ted H. Morton,
  • Ted H. Morton,
  • Shane J. Cross

DOI
https://doi.org/10.3389/fonc.2023.1229655
Journal volume & issue
Vol. 13

Abstract

Read online

From 8 December 2021 to 26 January 2023, tixagevimab–cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28–135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.

Keywords